Seven things every investor needs to know about Incannex Healthcare

Over its clinical platform, the company is developing regulated cannabis products. It has 28 clinical programmes in progress and holds one of the world’s largest and most diversified portfolios of patented cannabinoid drug formulations and psychedelic treatment regimes.

Edison’s 30 August 2022 initiation report, Addressing unmet needs via alternative approach, provides background on the company and its mission.

#1 Clinical development platform
The company intends to leverage its intellectual property and pre-existing public data for compounds through the pursuit of 505(b)(2) NDA regulatory pathways during clinical development to accelerate commercialisation and improve the probability of clinical success for its assets.

#2 Six key treatments
In February 2022, Incannex achieved its Nasdaq listing as it promoted its development pipeline for six lead assets for obstructive sleep apnoea, traumatic brain injury, inflammatory lung conditions, inflammatory bowel disease, rheumatoid arthritis and generalised anxiety disorder.

#3 Anti-inflammatory trials on track
In July 2022, the company initiated Phase I clinical trials for its anti-inflammatory medication IHL-675A, a combination of cannabidiol and hydroxychloroquine sulfate, which has demonstrated potential for improving symptoms of rheumatoid arthritis, inflammatory bowel disease and lung inflammation.

#4 Tackling the obstructive sleep apnoea market
Incannex has achieved proof-of-concept in Australia for IHL-42X, its lead asset for the treatment of obstructive sleep apnoea. The company intends to file an investigational new drug application (IND) for IHL-42X with the FDA in Q4 CY22 following positive Phase II results from its Australian clinical trial data.

#5 The impact of acquisition
In July 2022, Incannex completed the acquisition of APIRx Pharmaceuticals, a US biotechnology company focused on the development and manufacture of cannabinoid formulations. The deal enhances the company’s platform.

#6 Psilocybin: the new player in treating anxiety disorder
In collaboration with the Clinical Psychedelic Research Lab at Monash University, Incannex has begun studies in the use of psilocybin-assisted psychotherapy to treat generalised anxiety disorder (GAD). The move comes as it develops a second lead asset, Psi-GAD, which is set to complete pre-IND FDA clinical trials in Q422.

#7 A strengthening position despite market uncertainty
Incannex’s cash position as of 30 June 2022 was A$37.5m after raising A$24m at A$0.35 per share in May. Its top 40 shareholders hold 720.2k shares or 47.27%. As of 21 September 2022, Incannex’s market capitalisation was US$319m with a price of US$5.23 per ADR.

The company’s cannabinoid and psychedelic drug platform allows the company to discover therapies for patients with debilitating conditions.

For more information, visit Edison’s profile page for Incannex Healthcare.

IMPORTANT DISCLOSURES

Edison offers investor relations, consulting and research publication services to paying clients. In accordance with Section 17(b) of the US Securities Act of 1933, please note the following important disclosures relating to Edison and its client relationship with Incannex Healthcare (the “Company”).

Edison is engaged by the Company on a paid basis for investor relations services and this communication relates to those services. In connection with its investor relations engagement by the Company, Edison’s standard fees are $20,000 per month. Additional compensation may have accrued since the publication of this notice.

In addition, Edison is engaged by the Company to separately provide investment research coverage of its stock. In connection with its investment research coverage, Edison’s standard fees are £60,000 pa. Additional compensation may have accrued since the publication of this notice. No compensation relating to Edison’s investment research coverage is in any way contingent upon any positive opinions or conclusions in its research reports.

Edison’s investor relations services are independent of its research services, although Edison’s investor relations activities may utilize published Edison research as a source, among others, in connection with its activities. Edison’s investor relations and investment research personnel regularly, but separately, interact with the Company. All source materials relating to any investor relations materials of Edison should be considered to be directly attributable to information provided to Edison by the Company or the third-party sources noted in the communication. While third-party information used in the publication of Edison’s communications is typically compiled from publicly available sources that are believed to be accurate, complete and reliable, Edison does not guarantee the accuracy or completeness of information contained therein, and typically does not independently verify such information.

NOTE THAT ALL INVESTMENTS ARE SUBJECT TO INHERENT RISK AND ANY INVESTMENT IN THE COMPANY IS SUBJECT TO SIGNIFICANT RISKS THAT SHOULD BE ASSESSED BY ANY INVESTOR AND THEIR ADVISORS. PLEASE CLOSELY REVIEW THE COMPANY’S AVAILABLE PUBLIC DISCLOSURES, INCLUDING RISK FACTORS FOR SPECIFIC CONSIDERATION, WHICH ARE AVAILABLE THROUGH THE COMPANY’S INVESTOR RELATIONS WEBSITE, LINKED ABOVE.

This communication may include forward-looking statements that are subject to risks and uncertainties. Factors that could cause a company’s actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company’s products or services, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements relating to this communication are qualified in their entirety by this cautionary statement.

Edison is neither a FINRA-registered broker-dealer nor an SEC-registered investment adviser and does not provide any investment advisory or banking services. Edison’s investment research reports are bona fide publications of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. Edison does not offer or provide personal advice and its research provided is for informational purposes only. No mention of a particular security in any Edison communication constitutes a solicitation or recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison’s policies on personal dealing and conflicts of interest.